Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-02T17:01:09.023Z Has data issue: false hasContentIssue false
  • English
  • Français

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

Published online by Cambridge University Press:  16 April 2020

G.L. Larkin ,
A.L. Beautrais ,
R.R. Turelli ,
G. Sanacora ,
S. Powsner ,
M. Lippmann  and
J. Krystal
G.L. Larkin
Affiliation:
Emergency Medicine, New Haven, CT, USA
A.L. Beautrais
Affiliation:
Emergency Medicine, New Haven, CT, USA
R.R. Turelli
Affiliation:
Emergency Medicine, New Haven, CT, USA
G. Sanacora
Affiliation:
Psychiatry, Yale University School of Medicine, New Haven, CT, USA
S. Powsner
Affiliation:
Emergency Medicine and Psychiatry, Yale University School of Medicine, New Haven, CT, USA
M. Lippmann
Affiliation:
Emergency Medicine, New Haven, CT, USA
J. Krystal
Affiliation:
Psychiatry, Yale University School of Medicine, New Haven, CT, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Rapid-onset antidepressants could have important clinical impact if their benefits extended to ED patients. We examined preliminary feasibility, tolerability and efficacy of single-dose IV ketamine in depressed ED patients with suicide ideation (SI).

Methods

Fourteen depressed ED patients with SI received a single IV bolus of ketamine (0.2 mg/kg) over 1–2 minutes. Patients were monitored for 4 hours, then re-contacted daily for 10 days. Treatment response and time to remission were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) and Kaplan Meier survival analysis, respectively.

Results

Brief Psychiatric Rating Scale and Young Mania Rating Scale scores transiently increased in two subjects, consistent with ketamine's cognitive/behavioral effects in other populations. Mean MADRS scores fell significantly from 40.4 (SEM:1.8) at baseline to 11.5 (2.2) at 240 minutes. Median time to MADRS score ≤10 was 80 minutes (Interquartile Range: 0.67–24 hours). Suicide ideation scores (MADRS item 10) decreased significantly from 3.9 (SEM:0.4) at baseline to 0.6 (SEM:0.2) at 40 minutes post-administration, with improvements sustained over 10 days.

Conclusions

These data provide preliminary, open-label support for the feasibility and efficacy of ketamine as a rapid-onset antidepressant in the ED.

Type
P03-437
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1607
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.